JPRN-jRCT2080221295未知3 期
Therapeutic use of oral sodium phosphate (Z-521) in primary hypophosphatemic rickets (familial rickets, X-linked hypophosphatemia, vitamin D-resistant rickets)
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 1age old 至 <= 14age old（—）
- 性别
- All
入选标准
- •subjects diagnosed as primary hypophosphatemic rickets based on familial history, genetic test or laboratory test results
排除标准
- •subjects with hyperparathyroidism
研究者
相似试验
已完成
3 期
Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic RicketsPrimary Hypophosphatemic RicketsNCT01237288Zeria Pharmaceutical16
已完成
4 期
Oral bisphosphonate, alendronate, for the treatment of acute Charcot neuroarthropathy in diabetic patientsISRCTN86625608Tameside Hospital NHS Foundation Trust (UK)78
尚未招募
2 期
Combination oral chemotherapy in advanced ovarian cancerCTRI/2017/10/010219Aparna Sharma
已完成
不适用
Safety and efficacy of polyphosphate for the treatment of ulcerative colitis(AMU002-CR01)JPRN-UMIN000021555Asahikawa Medical University10
进行中（未招募）
1 期
Acute treatment and prophylaxis for acquired angioedemaAcquired angioedema due to C1-inhibitor deficiencyMedDRA version: 21.0Level: PTClassification code 10081035Term: Acquired C1 inhibitor deficiencySystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-000720-36-NLAcademisch Medisch Centrum3